Current Clinical Trials.
here for a printable pdf with a
brief synopsis of all of our open trials. Click title
of trial (below) to get a detailed fact sheet for each of our fully
Open Fully Funded Trials
• Mast Cell Tumors in Dogs: This fully funded study for Grade 2, stage 2a or 3a MCTs evaluates a new treatment. Candidates must have measurable tumors over 2 cm and no previous chemotherapy or radiation therapy; pet must not be a candidate for surgery, or surgery must have been declined by owner.
• Recurrent Mast Cell Tumors in Dogs: This fully funded clinical trial will evaluate at least one cycle of a novel therapeutic agent in dogs with measurable recurrent cutaneous mast cell tumors. Candidates must have at least one measurable tumor, no previous anti-cancer therapy within 21 days of enrollment, and no active bacterial infection requiring systemic antibiotic therapy within 7 days of enrollment.
• Solid Measurable Tumors / Soft Tissue Sarcoma: This fully funded clinical trial will evaluate at least one cycle of a novel therapeutic agent in dogs with measurable solid tumors. Dogs that meet the eligibility criteria will be eligible to receive up to 8 weekly intratumoral injections of the therapeutic agent. Dogs will also been seen for recheck visits following the dosing period for a total study period of 3 months.
Additional Open Trials
• Transitional Cell Carcinoma: Partially funded study aims to determine whether different NSAIDs have the same efficacy against transitional cell carcinoma. Goals of trial are to determine if piroxicam, a non-selective NSAID, and firocoxib, a highly selective NSAID, have equal efficacy, and help establish the mechanisms through which NSAIDs work in cancer therapy. Dogs with bladder masses are currently being recruited for inclusion and would receive piroxicam or firocoxib in combination with mitoxantrone chemotherapy, consistent with current standards of care.
• Canine Nasal Carcinoma: Partially funded, multi-institutional clinical study offered via affiliation with the Veterinary Radiation Therapy Oncology Group. Objective is to identify the activity of Toceranib (Palladia), a tyrosine kinase inhibitor, used alone or as a radiation sensitizing agent in treatment of canine nasal carcinomas. Recently, the presence of target receptors for Toceranib have been identified in canine nasal carcinomas and this non-randomized clinical study will examine the drug's efficacy, either alone or in combination with radiotherapy.
• Obstructive Transitional Cell Carcinoma: Study designed to alleviate urinary obstruction by utilizing palliative radiation therapy (five consecutive daily doses of radiation Mon - Fri), a urinary catheter, chemotherapy and piroxicam. Initial results have showed a 100 percent success rate at unblocking urinary obstruction in dogs with urinary transitional cell carcinoma.
• OSA in Greyhounds: In conjunction with the Greyhound Health and Wellness Program at Ohio State University, this study aims to determine if there is a genetic correlation among retired racing greyhounds that develop OSA. Five doses of chemotherapy agent provided free of charge to qualified greyhounds in exchange for a small blood sample.
• Brain Tumors: Designed to deliver two treatments of hypo-fractionated radiation therapy to dogs and cats with brain tumors in a modified radiosurgical Linear Accelerator-based approach. Animals then receive two fractions of radiation given two days apart. Goal of the study is to evaluate effects of a modified radiosurgical and potentially palliative approach for brain tumor patients who are not candidates for standard definitive radiation therapy.
Non-Cancer Related Radiation Therapy Study:
• Osteoarthritis: This Veterinary Cancer Group and Advanced Critical Care of Los Angeles partially funded prospective study is designed to investigate the palliative effects of external beam low dose radiation therapy for dogs with refractory osteoarthritis. Human trials have demonstrated long term pain relief and functional gain in 50-75% of patients treated; animal models have shown significant reduction of inflammation and joint effusion in affected radiated joints. Dogs enrolled will receive three doses of radiation, lower than would be of concern for any side effects, on three consecutive days and be followed for 1 year after completion of radiation. Initial and follow up orthopedic exams performed by a board certified surgeon. Eligible candidates must have orthogonal radiographic views of the joint, CBC and chemistry profile, and urine test at their family veterinarian. Concurrent NSAIDs or steroid usage do not disqualify enrollment.
Please call the Veterinary Cancer Group location nearest you for more information about any of these trials or to make an appointment with one of our oncologists. All potential trial candidates require a consultation to determine eligibility.
|Sign up to receive our e-news|
Orange County (949) 552-8274
Los Angeles (310) 558-6120
San Fernando Valley (818) 888-6882
South Orange County (949) 262-5150